LSV Associates, LLC → ALX Oncology Holdings Inc. ALXO

Stake: 2.20% Shares: 1,549,132 CUSIP: 00166B105 Class: Common Stock, par value $0.001 per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 36/100

Active Schedule 13D filer baseline
Held by 1 tracked 13F institutional manager
2 NPORT-P mutual funds holding CUSIP
Moderate short days-to-cover (3.6 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

4 13D/G filings on this issuer

3 other filings besides this one

Filer Track Record

1 filings by this filer

0 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 3.63

5,976,398 shares short · +5.3% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $23K

Point72 Asset Mgmt

Post-Filing Returns · since 2026-05-27 on ALXO

+1 day

-3.6%

+5 days

-8.2%

+30 days

+4.1%

+60 days

+3.1%

+90 days

—

+180 days

—

Anchor price 1.96 on closest trading day on/after 2026-05-27. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Other 13D/G Filings on ALX Oncology Holdings Inc.

Filed	Form	Filer	Stake	Shares
2026-10-16	SCHEDULE 13D/A	venBio Global Strategic Fund, L.P.	9.99%	4,307,034	view →
2026-07-27	SCHEDULE 13G	BlackRock, Inc.	—	—	view →
2021-06-15	SC	Logos Global Management LP	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →